Published in Int J Radiat Oncol Biol Phys on July 15, 1998
Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004. Br J Haematol (2008) 3.21
Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood (2006) 1.98
Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study. BMC Cancer (2006) 1.68
A review for solitary plasmacytoma of bone and extramedullary plasmacytoma. ScientificWorldJournal (2012) 1.67
Extramedullary plasmacytomas in the head and neck region. Eur Arch Otorhinolaryngol (2008) 1.33
Bone marrow immunohistology of plasma cell neoplasms. J Clin Pathol (2003) 1.17
Outcomes of patients with POEMS syndrome treated initially with radiation. Blood (2013) 1.02
Trends and outcomes of modern staging of solitary plasmacytoma of bone. Am J Hematol (2012) 1.01
Metastatic haematological malignancy presenting as a sellar mass. BMJ Case Rep (2012) 0.84
Rapid progression of solitary plasmacytoma to multiple myeloma in lumbar vertebra. J Korean Neurosurg Soc (2013) 0.79
Anal canal plasmacytoma-An uncommon presentation site. Rep Pract Oncol Radiother (2010) 0.78
Solitary extramedullary plasmacytoma of the liver without systemic monoclonal gammopathy. J Korean Med Sci (2007) 0.75
Effects of Radiotherapy in the treatment of multiple myeloma: a retrospective analysis of a Single Institution. Radiat Oncol (2015) 0.75
Plasmacytoma to the Axis Mimicking Metastatic Paraganglioma: Circumferential Reconstruction via Posterior Approach. Korean J Spine (2015) 0.75
[Solitary bone plasmacytoma: experience of the National Institute of Oncology, Rabat (INO)]. Pan Afr Med J (2014) 0.75
[Solitary bone plasmacytoma: about 3 cases and review of the literature]. Pan Afr Med J (2016) 0.75
Oral lesion as unusual first manifestation of multiple myeloma: case reports and review of the literature. Case Rep Hematol (2014) 0.75
Contribution of surgery in solitary plasmacytoma of spine; a case report. Arch Bone Jt Surg (2014) 0.75
Helical tomotherapy and systemic targeted therapies in solitary plasmacytoma: Pilot study. World J Radiol (2013) 0.75
Solitary plasmacytoma of temporal bone: A rare case report. Asian J Neurosurg (2017) 0.75
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys (1995) 15.12
Identification of the genomic locations of duplicate nucleotide sequences in maize by analysis of restriction fragment length polymorphisms. Genetics (1988) 11.26
Competency development in public health leadership. Am J Public Health (2000) 3.84
c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med (2001) 3.51
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol (2000) 3.50
A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol (2004) 3.49
Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med (1984) 3.06
Clinically relevant end points and new drug approvals for myeloma. Leukemia (2007) 2.91
Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood (2000) 2.87
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia (2007) 2.76
Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer (2001) 2.59
Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA (1969) 2.56
Production of "authentic" poliovirus RNA-dependent RNA polymerase (3D(pol)) by ubiquitin-protease-mediated cleavage in Escherichia coli. Protein Expr Purif (1999) 2.24
Benzene and multiple myeloma: appraisal of the scientific evidence. Blood (1999) 2.05
Clinical course of solitary extramedullary plasmacytoma. Radiother Oncol (1999) 2.05
Primary dexamethasone treatment of multiple myeloma. Blood (1992) 2.02
Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med (1980) 1.91
The effect of overall treatment time on the outcome of definitive radiotherapy for localized prostate carcinoma: the Radiation Therapy Oncology Group 75-06 and 77-06 experience. Int J Radiat Oncol Biol Phys (1991) 1.88
Cellular DNA content as a marker of human multiple myeloma. Blood (1980) 1.83
Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med (1982) 1.79
Leginon: a system for fully automated acquisition of 1000 electron micrographs a day. Ultramicroscopy (1999) 1.75
Catalysis by metal-activated hydroxide in zinc and manganese metalloenzymes. Annu Rev Biochem (1999) 1.67
Analysis of the probability and risk of cause-specific failure. Int J Radiat Oncol Biol Phys (1994) 1.65
Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys (1997) 1.65
Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course. Am J Clin Pathol (2001) 1.65
Standards for diagnosis and management of invasive breast carcinoma. American College of Radiology. American College of Surgeons. College of American Pathologists. Society of Surgical Oncology. CA Cancer J Clin (1998) 1.65
Reliability of a urine dipstick in emergency department patients. Ann Emerg Med (1989) 1.61
Non-Hodgkin's lymphomas involving the uterus: a clinicopathologic analysis of 26 cases. Mod Pathol (2000) 1.55
Anaplastic myeloma with massive extramedullary involvement. Report of two cases. Cancer (1983) 1.54
Primary plasma cell leukaemia. Br J Haematol (1994) 1.54
Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood (1998) 1.54
Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys (2000) 1.54
2-Chlorodeoxyadenosine in the treatment of multiple myeloma. Blood (1992) 1.52
Extraosseous multiple myeloma: imaging features. AJR Am J Roentgenol (1993) 1.52
Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys (1989) 1.52
Probing erectile function: S-(2-boronoethyl)-L-cysteine binds to arginase as a transition state analogue and enhances smooth muscle relaxation in human penile corpus cavernosum. Biochemistry (2001) 1.51
Risk factors for local and regional recurrence in patients with resected N0-N1 non-small-cell lung cancer, with implications for patient selection for adjuvant radiation therapy. Ann Oncol (2012) 1.50
Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys (1991) 1.50
Plasma cell granuloma of the nasal cavity treated by radiation therapy. Cancer (1991) 1.45
Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol (1993) 1.44
Melphalan therapy for plasma cell myeloma. Blood (1968) 1.43
Adenocarcinoma of the lung: recent results from the Veterans Administration Lung Group. Am Rev Respir Dis (1979) 1.41
Outcomes of high-dose unilateral kidney irradiation in patients with gastric lymphoma. Int J Radiat Oncol Biol Phys (1998) 1.41
Enhancement of experimental metastasis by tumor necrosis factor. J Exp Med (1993) 1.40
Is prolonged survival possible for patients with supraclavicular node metastases in non-small cell lung cancer treated with chemoradiotherapy?: Analysis of the Radiation Therapy Oncology Group experience. Int J Radiat Oncol Biol Phys (1999) 1.39
Is long-term survival possible with external beam irradiation for stage D1 adenocarcinoma of the prostate? Cancer (1992) 1.38
Prognostic factors with high-dose melphalan for refractory multiple myeloma. Blood (1988) 1.36
Combination chemotherapy for multiple myeloma. Cancer (1972) 1.36
Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys (2000) 1.34
Histamine and peptic ulcer: influence of sample-taking on the precision and accuracy of fluorometric histamine assay in biopsies of human gastric mucosa. Agents Actions (1980) 1.34
Localized and indolent myeloma. Blood (1980) 1.33
High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood (1986) 1.32
High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med (1991) 1.32
High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med (1986) 1.31
Prognostic factors in multiple myeloma. Cancer (1975) 1.29
Cytoplasmic immunoglobulin content in multiple myeloma. J Clin Invest (1985) 1.29
Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant (2001) 1.27
Plasma cell myeloma--new biological insights and advances in therapy. Blood (1989) 1.25
Integrated in situ soil remediation technology: the lasagna process. Environ Sci Technol (1995) 1.24
Histamine content and mast cells in human gastric and duodenal mucosa. Agents Actions (1978) 1.24
The growth fraction of human myeloma cells. Blood (1981) 1.24
Unmaintained remissions in multiple myeloma. Blood (1978) 1.22
Identification of specific residues of human interleukin 2 that affect binding to the 70-kDa subunit (p70) of the interleukin 2 receptor. Proc Natl Acad Sci U S A (1988) 1.22
In response to Bentzen et al., IJROBP 32:1531-1534; 1995. Int J Radiat Oncol Biol Phys (1995) 1.21
Monoclonal antibodies to E92, an endothelial cell surface antigen. Arteriosclerosis (1983) 1.21
Single-dose therapy with trimethoprim-sulfamethoxazole for urinary tract infection in women. Rev Infect Dis (1982) 1.21
Cranial irradiation in cancer of the lung of all cell types. JAMA (1981) 1.21
Curability of solitary bone plasmacytoma. J Clin Oncol (1992) 1.20
p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst (1997) 1.19
Treatment of patients with lymphomas of the uterus or cervix with combination chemotherapy and radiation therapy. Cancer (1995) 1.19
CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplant (2009) 1.19
Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD). Hematology (2010) 1.18
Localized primary non-Hodgkin lymphoma of the breast. Am J Clin Oncol (1998) 1.18
High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma. Ann Intern Med (1989) 1.18
Lymphoma of the nasal cavity and paranasal sinuses: improved outcome and altered prognostic factors with combined modality therapy. Cancer (1997) 1.17
Nonsecretory multiple myeloma. Am J Hematol (1982) 1.17
Ploidy and proliferative characteristics in monoclonal gammopathies. Blood (1982) 1.15
High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood (1987) 1.15
PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma. Leukemia (2012) 1.15
Risk of brain metastasis from small cell carcinoma of the lung related to length of survival and prophylactic irradiation. Cancer Treat Rep (1981) 1.14
Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology (2007) 1.14
Localized primary malignant lymphoma of bone. Int J Radiat Oncol Biol Phys (1997) 1.14
Prognostic features of asymptomatic multiple myeloma. Br J Haematol (1997) 1.13
Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma. Ann Oncol (2005) 1.13